



Medicine Supply Notification

MSN/2025/021

Triamcinolone acetonide 10mg/ml (Adcortyl® ampoules) and 40mg/ml (Kenalog® vials) suspension for injection

Tier 2 – medium impact*

Date of issue: 07/04/2025

Link: [Medicines Supply Tool](#)

Summary

- Triamcinolone acetonide 10mg/ml (Adcortyl® ampoules) and 40mg/ml (Kenalog® vials) suspension for injection are being **discontinued** with stock expected to be exhausted by early June 2025.
- Dexamethasone sodium phosphate 3.3mg/ml and 3.8mg/ml injections are available and can support increased demand (see Supporting information).
- Hydrocortisone sodium succinate 100mg powder for solution for injection is available and can support increased demand (see Supporting information).
- Methylprednisolone sodium succinate (Solu-Medrone®) 500mg and 1g injection and methylprednisolone acetate (Depo-Medrone®) 40mg/ml injection are available and can support increased demand (see Supporting information).
- Unlicensed supplies of triamcinolone acetonide 10mg/1ml suspension for injection ampoules and triamcinolone acetonide 40mg/1ml suspension for injection vials have been sourced; lead times may vary.

Actions Required

Clinicians in primary and secondary care should:

- review patients and consider prescribing alternative steroid injections (see Supporting information); or
- consider prescribing unlicensed imports of triamcinolone acetonide 10mg/1ml suspension for injection ampoules and triamcinolone acetonide 40mg/1ml suspension for injection vials only where licensed alternatives are not considered appropriate;
- seek advice from specialists on management options, where the above options are not considered appropriate.

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

Supporting information

Corticosteroid preparation	Licensed indication	Route of administration
Adcortyl®*	- Alleviating joint pain, swelling and stiffness associated with rheumatoid arthritis and osteoarthritis, with an inflammatory component, also for bursitis, epicondylitis, and tenosynovitis. ‡ - Lichen simplex chronicus (neuro-dermatitis), granuloma annulare, lichen planus, keloids, alopecia areata and hypertrophic scars. §	Intra-articular‡, Intradermal §
Kenalog®*	- Alleviating joint pain, swelling and stiffness associated with rheumatoid arthritis and osteoarthritis, with an inflammatory component, also for bursitis, epicondylitis, and tenosynovitis. ‡ - Treatment of conditions where sustained corticosteroid treatment is required [In practice, the use of Kenalog® for treating hayfever is discouraged]. ¶	Intra-articular‡, intramuscular ¶
Available corticosteroid injections that can support increase in demand		
Dexamethasone 3.3mg/ml and 3.8mg/ml solution for injection	Endocrine disorders, non-endocrine corticosteroid-responsive conditions, local administration for soft-tissue disorders, intra-articular disorders and soft tissue disorders	Intravenous, intramuscular, subcutaneous, intra-articular, intrabursal, intralesional
Hydrocortisone sodium succinate 100mg powder for solution for injection	Any condition in which rapid and intense corticosteroid effect is required	Intravenous, intramuscular
Methylprednisolone (Depo-Medrone®) 40mg/1ml suspension for injection	Rheumatic disorders, collagen diseases/arthritis, dermatological diseases, allergic states, GI diseases, respiratory diseases, TB meningitis, soft-tissue disorders	Intramuscular, intra-articular, peri-articular, intrabursal, into tendon sheath, intralesional
Methylprednisolone (Solu-Medrone®) 500mg and 1g powder and solvent for solution for injection vials	Any condition in which rapid and intense corticosteroid effect is required	Intravenous, intramuscular

*Off label uses also reported in practice

Links to further information

[SmPC Adcortyl® 10mg/1ml suspension for injection ampoules](#)

[SmPC Kenalog® 40mg/1ml suspension for injection vials](#)

[SmPC dexamethasone sodium phosphate \(3.3mg/ml or 3.8mg/ml\) injection](#)

[SmPC hydrocortisone sodium succinate 100mg powder for solution for injection](#)

[SmPC methylprednisolone sodium succinate \(Solu-Medrone®\) injection](#)

[SmPC methylprednisolone acetate \(Depo-Medrone®\) injection](#)

[BNF triamcinolone acetonide](#)

[BNF corticosteroids inflammatory disorders](#)

[NICE CKS rheumatoid arthritis](#)

[NICE CKS osteoarthritis](#)

Guidance on ordering and prescribing unlicensed imports

The following specialist importers have confirmed they can source unlicensed triamcinolone acetonide 10mg/ml and/or triamcinolone acetonide 40mg/ml injections (please note there may be other companies that can also source supplies):



Department of Health & Social Care

- Alium medical
- Chemys
- Durbin
- Genetech
- Mawdsleys



- Qmed
- Smartway
- Tanner Pharma
- Target

Any decision to prescribe an unlicensed medicine must consider the relevant guidance and NHS Trust or local governance procedures. Unlicensed imports do not undergo any central quality assessment or suitability evaluation. Therefore, any import must be locally assessed in line with local unlicensed medicines processes.

Please see the links below for further information:

- [The supply of unlicensed medicinal products](#), Medicines and Healthcare products Regulatory Agency (MHRA)
- [Professional Guidance for the Procurement and Supply of Specials](#), Royal Pharmaceutical Society
- [Prescribing unlicensed medicines](#), General Medical Council (GMC)

Enquiries

Enquiries from NHS Trusts in England should in the first instance be directed to your Specialist Pharmacy Service Regional Pharmacy Procurement Team, who will escalate to national teams if required.

REGION	Lead RPPS	Email	Associate RPPS	Email
Midlands				
East of England				
London				
North East and Yorkshire				
North West				
South East				
South West				

Scotland

nss.nhssmedicineshortages@nhs.scot

Wales

MedicinesShortages@gov.wales

Northern Ireland

RPHPS.Admin@northerntrust.hscni.net

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

All other organisations should send enquiries about this notice to the DHSC Medicine Supply Team quoting reference number MSN/2025/021

Email: DHSCmedicinesupplyteam@dhsc.gov.uk.